TABLE 2.
Patient Outcomes Disaggregated by Patient Demographic and Clinical Characteristics
| Outcome | Total | |||||||
| Deceased | Transferred out | Stopped ART | Migrated | Reengaged | Alive: ART unknown | Still LTFU | All LTFU | |
| 120 | 315 | 75 | 49 | 225 | 111 | 122 | 1017 | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||
| Sex (P < 0.001) | ||||||||
| Female | 70 (9.1) | 258 (33.6) | 48 (6.3) | 43 (5.6) | 164 (21.4) | 90 (11.7) | 94 (12.2) | 767 (75.4) |
| Male | 50 (20.0) | 57 (22.8) | 27 (10.8) | 6 (2.4) | 61 (24.4) | 21 (8.4) | 28 (11.2) | 250 (24.6) |
| Age (P < 0.001) | ||||||||
| 18–29 | 17 (5.1) | 117 (35.1) | 24 (7.2) | 25 (7.5) | 61 (18.3) | 46 (13.8) | 43 (12.9) | 333 (32.7) |
| 30–44 | 55 (11.4) | 147 (30.4) | 37 (7.6) | 21 (4.3) | 116 (24.0) | 50 (10.3) | 58 (12.0) | 484 (47.6) |
| 45–59 | 27 (19.1) | 38 (26.9) | 11 (7.8) | 2 (1.4) | 35 (24.8) | 13 (9.2) | 15 (10.6) | 141 (13.9) |
| 60+ | 21 (36.2) | 13 (22.4) | 3 (5.2) | 1 (1.7) | 12 (20.7) | 2 (3.4) | 6 (10.3) | 58 (5.7) |
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 1 (0.1) |
| ART reason (P < 0.001) | ||||||||
| Non-PMTCT | 110 (14.9) | 233 (31.6) | 47 (6.4) | 28 (3.8) | 171 (23.2) | 66 (8.9) | 82 (11.1) | 737 (72.5) |
| PMTCT | 10 (3.6) | 82 (29.3) | 28 (10.0) | 21 (7.5) | 54 (19.3) | 45 (16.1) | 40 (14.3) | 280 (27.5) |
| ART start yr (P = 0.251) | ||||||||
| 2014 | 28 (13.3) | 58 (27.5) | 14 (6.6) | 18 (8.5) | 50 (23.7) | 19 (9.0) | 24 (11.4) | 211 (20.7) |
| 2015 | 41 (9.9) | 149 (36.0) | 33 (8.0) | 16 (3.9) | 82 (19.8) | 44 (10.6) | 49 (11.8) | 414 (40.7) |
| 2016 | 46 (13.1) | 100 (28.6) | 24 (6.9) | 14 (4.0) | 82 (23.4) | 41 (11.7) | 43 (12.3) | 350 (34.4) |
| 2017 | 5 (11.9) | 8 (19.0) | 4 (9.5) | 1 (2.4) | 11 (26.2) | 7 (16.7) | 6 (14.3) | 42 (4.1) |
| Time on ART (P < 0.001) | ||||||||
| ≤3 mo | 54 (16.6) | 89 (27.3) | 29 (8.9) | 13 (4.0) | 47 (14.5) | 41 (12.6) | 52 (16.0) | 325 (32.0) |
| 3–6 mo | 18 (9.5) | 62 (32.6) | 13 (6.8) | 8 (4.2) | 31 (16.3) | 30 (15.8) | 28 (14.7) | 190 (18.7) |
| 6–12 mo | 25 (11.0) | 79 (34.6) | 12 (5.3) | 17 (7.5) | 42 (18.4) | 25 (11.0) | 28 (12.3) | 228 (22.4) |
| 12–24 mo | 16 (7.3) | 76 (34.7) | 17 (7.8) | 9 (4.1) | 75 (34.2) | 13 (5.9) | 13 (5.9) | 219 (21.5) |
| >24 mo | 7 (12.7) | 9 (16.4) | 4 (7.3) | 2 (3.6) | 30 (54.5) | 2 (3.6) | 1 (1.8) | 55 (5.4) |
| Baseline CD4 (P < 0.001) | ||||||||
| <100 | 50 (24.3) | 64 (31.1) | 8 (3.9) | 4 (1.9) | 38 (18.4) | 13 (6.3) | 29 (14.1) | 206 (20.2) |
| 100–199 | 32 (17.3) | 46 (24.9) | 16 (8.6) | 8 (4.3) | 41 (22.2) | 19 (10.3) | 23 (12.4) | 185 (18.2) |
| 200–349 | 19 (7.3) | 69 (26.4) | 23 (8.8) | 12 (4.6) | 63 (24.1) | 43 (16.5) | 32 (12.3) | 261 (25.7) |
| 350–499 | 11 (5.7) | 72 (37.3) | 16 (8.3) | 14 (7.3) | 36 (18.6) | 20 (10.4) | 24 (12.4) | 193 (19.0) |
| 500+ | 8 (5.5) | 53 (36.5) | 11 (7.6) | 10 (6.9) | 41 (28.3) | 12 (8.3) | 10 (6.9) | 145 (14.3) |
| Missing | 0 (0) | 11 (40.7) | 1 (3.7) | 1 (3.7) | 6 (22.2) | 4 (14.8) | 4 (14.8) | 27 (2.6) |
| Baseline WHO stage (P = 0.017) | ||||||||
| I | 65 (9.0) | 230 (31.8) | 55 (7.6) | 38 (5.3) | 159 (22.0) | 88 (12.2) | 87 (12.0) | 722 (71.0) |
| II | 21 (14.7) | 42 (29.4) | 12 (8.4) | 6 (4.2) | 34 (23.8) | 11 (7.7) | 17 (11.9) | 143 (14.1) |
| III | 26 (20.1) | 39 (30.2) | 7 (5.4) | 4 (3.1) | 28 (21.7) | 9 (7.0) | 16 (12.4) | 129 (12.7) |
| IV | 5 (50.0) | 1 (10.0) | 1 (10.0) | 0 (0) | 2 (20.0) | 0 (0) | 1 (10.0) | 10 (1.0) |
| Missing | 3 (23.1) | 3 (23.1) | 0 (0) | 1 (7.7) | 2 (15.4) | 3 (23.1) | 1 (7.7) | 13 (1.3) |
| Refill schedule (P < 0.001) | ||||||||
| 1 mo | 84 (12.5) | 210 (31.2) | 48 (7.1) | 30 (4.5) | 143 (21.3) | 77 (11.4) | 80 (11.9) | 672 (66.1) |
| 2 mo | 24 (10.3) | 71 (30.5) | 21 (9.0) | 14 (6.0) | 43 (18.4) | 24 (10.3) | 36 (15.5) | 233 (22.9) |
| 3 mo | 9 (11.4) | 30 (38.0) | 3 (3.8) | 5 (6.3) | 18 (22.8) | 9 (11.4) | 5 (6.3) | 79 (7.8) |
| >3 mo | 3 (9.1) | 4 (12.1) | 3 (9.1) | 0 (0) | 21 (63.6) | 1 (3.0) | 1 (3.0) | 33 (3.2) |
| Health facility (P < 0.001) | ||||||||
| Agincourt | 27 (9.9) | 66 (24.3) | 15 (5.5) | 11 (4.0) | 110 (37.1) | 21 (7.7) | 22 (8.1) | 272 (26.7) |
| Belfast | 16 (8.6) | 52 (28.0) | 13 (7.0) | 12 (6.4) | 32 (17.2) | 29 (15.6) | 32 (17.2) | 186 (18.3) |
| Cunningmore | 11 (19.0) | 21 (36.2) | 8 (13.8) | 1 (1.7) | 7 (12.1) | 5 (8.6) | 5 (8.6) | 58 (5.7) |
| Justicia | 20 (16.7) | 30 (25.0) | 13 (10.8) | 7 (5.8) | 14 (11.7) | 11 (9.2) | 25 (20.8) | 120 (11.8) |
| Kildare | 16 (13.7) | 50 (42.7) | 10 (8.5) | 8 (6.8) | 14 (12.0) | 9 (7.7) | 10 (8.5) | 117 (11.5) |
| Lillydale | 19 (11.4) | 51 (30.7) | 9 (5.4) | 7 (4.2) | 37 (22.3) | 24 (14.5) | 19 (11.4) | 166 (16.3) |
| Thulamahashe | 3 (12.0) | 4 (16.0) | 1 (4.0) | 0 (0) | 7 (28.0) | 6 (24.0) | 4 (16.0) | 25 (2.4) |
| Xanthia | 9 (12.2) | 41 (55.4) | 6 (8.1) | 3 (4.0) | 4 (5.4) | 6 (8.1) | 5 (6.8) | 74 (7.3) |
| Time since last appointment (P < 0.001) | ||||||||
| ≤1 yr | 48 (9.1) | 146 (27.8) | 40 (7.6) | 16 (3.0) | 171 (32.5) | 51 (9.7) | 54 (10.3) | 526 (51.7) |
| 1–2 yrs | 53 (14.4) | 134 (36.3) | 26 (7.0) | 19 (5.1) | 46 (12.5) | 44 (11.9) | 47 (12.7) | 369 (36.3) |
| >2 yrs | 19 (15.6) | 35 (28.7) | 9 (7.4) | 14 (11.5) | 8 (6.6) | 16 (13.1) | 21 (17.2) | 122 (12.0) |
| AHDSS outcome (P < 0.001) | ||||||||
| Still in HDSS | 17 (3.4) | 177 (35.0) | 52 (10.3) | 7 (1.4) | 141 (27.9) | 111 (22.0) | 0 (0) | 505 (49.7) |
| Deceased | 70 (94.6) | 4 (5.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 74 (7.3) |
| Migrated | 22 (8.1) | 86 (31.8) | 19 (7.0) | 34 (12.6) | 58 (21.5) | 0 (0) | 51 (18.9) | 270 (26.5) |
| Not linked | 11 (6.5) | 48 (28.6) | 4 (2.4) | 8 (4.8) | 26 (15.5) | 0 (0) | 71 (42.3) | 168 (16.5) |